Clearmind Medicine (CMND) 6-K 16 Sep 24 Condensed Interim Consolidated Financial Statements Financial data

Document And Entity Information

Document And Entity Information	9 Months Ended
	Jul. 31, 2024
Document Information Line Items
Entity Registrant Name	Clearmind Medicine Inc.
Document Type	6-K
Current Fiscal Year End Date	--10-31
Amendment Flag	false
Entity Central Index Key	0001892500
Document Period End Date	Jul. 31, 2024
Entity File Number	001-41557

Condensed Interim Consolidated

Condensed Interim Consolidated Statements of Financial Position (Unaudited) - USD ($)	Jul. 31, 2024	Oct. 31, 2023
Current assets
Cash and cash equivalents	$ 7,679,648	$ 5,427,739
Other receivables	82,745	104,320
Short-term investment (Note 3)		86,112
Prepaid expenses	123,765	40,403
Related parties (Note 4b)	108,597	136,002
Total current assets	7,994,755	5,794,576
Non-current assets
Property and equipment	355	1,727
Intangible assets	111,087	119,310
Restricted cash	7,242	37,675
Right-of-use asset (Note 4c)	59,925
Total non-current assets	178,609	158,712
Total assets	8,173,364	5,953,288
Current liabilities
Accounts payable and accrued liabilities	276,744	617,004
Due to related parties (Note 4a)	48,577	42,433
Derivative warrant liabilities (Note 5)	4,314,223	4,310,379
Short-term portion of lease liabilities (Note 4c)	35,320
Total current liabilities	4,674,864	4,969,816
Non- current liabilities
Long-term lease liabilities (Note 4c)	25,578
Total non- current liabilities	25,578	4,969,816
Total liabilities	4,700,442	4,969,816
Shareholders’ equity
Share capital and share premium (Note 6)	23,800,735	17,131,223
Warrants (Note 7)	459,341	459,341
Share-based payment reserve (Notes 8,9)	2,372,093	2,182,221
Accumulated other comprehensive loss	(21,250)	(21,250)
Accumulated deficit	(23,137,997)	(18,768,063)
Total shareholders’ equity	3,472,922	983,472
Total liabilities and shareholders’ equity	$ 8,173,364	$ 5,953,288

Condensed Interim Consolidate_2

Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)		3 Months Ended		9 Months Ended
		Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Operating expenses
General and administrative		$ 1,125,365	$ 838,925	$ 3,262,427	$ 3,422,798
Research and development, net		345,883	263,954	896,317	1,169,156
Total operating expenses		1,471,248	1,102,879	4,158,744	4,591,954
Finance income (expenses)
Changes in fair value of derivative warrant liabilities (Note 5)		(643,225)	482,331	(83,080)	121,774
Unrealized gain (loss) on short-term investment (Note 3)			(12,222)	415,826	(70,971)
Realized loss on short-term investment (Note 3)				(423,438)
Foreign exchange gain (loss)		(5,380)	33,645	(2,709)	(61,711)
Other finance income, net		85,024	17,307	179,555	41,288
Total finance income (expenses)		(563,581)	521,061	86,154	30,380
Other income (expenses)
Other expenses		(16,498)		(16,498)
Dividend received					16,555
Total other income (expenses)		(16,498)		(16,498)	16,555
Loss before taxes		(2,051,327)	(581,818)	(4,089,088)	(4,545,019)
Tax income (expenses)		(42,590)	6,631	(280,846)	(6,019)
Net Loss and Comprehensive loss		$ (2,093,917)	$ (575,187)	$ (4,369,934)	$ (4,551,038)
Loss per share, basic (in Dollars per share)		$ (0.59)	$ (2.43)	$ (1.58)	$ (31.14)
Weighted average number of shares for the purposes of basic loss per share (in Shares)	[1]	3,559,860	236,295	2,773,384	146,163
[1]On November 28, 2023, the Company effected a 1-for-30 reverse split of its issued and outstanding common shares, pursuant to which holders of the Company’s common shares received 0.0333 of a common share for every one common share then held. All share data prior to the date of the reverse share split has been retrospectively adjusted.

Condensed Interim Consolidate_3

Condensed Interim Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares		3 Months Ended		9 Months Ended
		Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Profit or loss [abstract]
Loss per share, diluted		$ (0.59)	$ (2.43)	$ (1.58)	$ (31.14)
Weighted average number of shares for the purposes of diluted loss per share	[1]	3,559,860	236,295	2,773,384	146,163
[1]On November 28, 2023, the Company effected a 1-for-30 reverse split of its issued and outstanding common shares, pursuant to which holders of the Company’s common shares received 0.0333 of a common share for every one common share then held. All share data prior to the date of the reverse share split has been retrospectively adjusted.

Condensed Interim Statements of

Condensed Interim Statements of Changes in Shareholders’ Equity (Deficit) (Unaudited) - USD ($)		Share capital and share premium	Warrants	Share-based payment reserve	Accumulated other comprehensive income	Accumulated deficit	Total
Balance at Oct. 31, 2022		$ 6,706,644	$ 459,110	$ 1,896,724	$ (21,250)	$ (10,147,226)	$ (1,105,998)
Balance (in Shares) at Oct. 31, 2022	[1]	43,992
Net loss for the period						(4,551,038)	(4,551,038)
Issuance of common shares		$ 6,026,327		337,579			6,363,906
Issuance of common shares (in Shares)	[1]	38,462
Common shares and warrants issued to XYLO TECHNOLOGIES LTD. (formerly Medigus Ltd.)		$ 296,845	231				297,076
Common shares and warrants issued to XYLO TECHNOLOGIES LTD. (formerly Medigus Ltd.) (in Shares)	[1]	1,494
Issuance of common shares, pre-funded warrants and warrants		$ 1,455,832					1,455,832
Issuance of common shares, pre-funded warrants and warrants (in Shares)	[1]	150,191
Issuance of common shares upon vesting of restricted stock units		$ 198,265		(198,265)
Issuance of common shares upon vesting of restricted stock units (in Shares)	[1]	806
Share-based compensation		$ 147,965		174,560			322,525
Share-based compensation (in Shares)	[1]	2,330
Balance at Jul. 31, 2023		$ 14,831,878	459,341	2,210,598	(21,250)	(14,698,264)	2,782,303
Balance (in Shares) at Jul. 31, 2023	[1]	237,275
Balance at Oct. 31, 2023		$ 17,131,223	459,341	2,182,221	(21,250)	(18,768,063)	983,472
Balance (in Shares) at Oct. 31, 2023	[1]	607,337
Net loss for the period						(4,369,934)	(4,369,934)
Issuance of common shares, pre-funded warrants and warrants		$ 1,459,815					1,459,815
Issuance of common shares, pre-funded warrants and warrants (in Shares)	[1]	1,500,000
Exercise of warrants		$ 4,594,808					4,594,808
Exercise of warrants (in Shares)	[1]	1,500,274
Issuance of common shares upon vesting of restricted stock units		$ 511,190		(511,190)
Issuance of common shares upon vesting of restricted stock units (in Shares)	[1]	306,838
Share-based compensation		$ 103,699		701,062			804,761
Share-based compensation (in Shares)	[1]	64,794
Balance at Jul. 31, 2024		$ 23,800,735	$ 459,341	$ 2,372,093	$ (21,250)	$ (23,137,997)	$ 3,472,922
Balance (in Shares) at Jul. 31, 2024	[1]	3,979,243
[1]On November 28, 2023, the Company effected a 1-for-30 reverse split of its issued and outstanding common shares, pursuant to which holders of the Company’s common shares received 0.0333 of a common share for every one common share then held.

Condensed Interim Consolidate_4

Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jul. 31, 2024	Jul. 31, 2023
Operating activities
Net loss	$ (4,369,934)	$ (4,551,038)
Adjustments for:
Amortization of intangible assets	8,223	12,509
Amortization of right-of-use asset	29,965	35,381
Interest on lease liability	3,924	2,907
Exchange rate differences	2,288	(622)
Dividend received		16,555
Share issuance costs allocated to derivate warrant liability	115,046
Depreciation of property and equipment	1,372	5,603
Changes in fair value of derivative warrant liability	83,080	(121,774)
Share-based compensation	701,374	329,032
Unrealized (gain) loss on short-term investment	(415,826)	70,971
Realized loss on short-term investment	423,438
Tax expenses	39,759	6,019
Changes in working capital:
Decrease (increase) in other receivables	54,820	(153,550)
Increase in prepaid expenses	(83,380)	(136,599)
Decrease in accounts payable and accrued liabilities	(382,275)	(898,795)
Increase (decrease) in due to / from related parties	6,612	(164,903)
Net cash used in operating activities	(3,781,514)	(5,548,304)
Investing activities
Proceeds from sale of short-term investment	78,500
Restricted Cash	33,803	7,686
Net cash generated in investing activities	112,303	7,686
Financing activities
Proceeds from issuance of common shares and warrants, net of issuance costs (Note 6c (iii))	1,824,773	9,300,048
Proceeds received from issuance of shares	103,387
Proceeds received from exercise of warrants (Notes 6c (ii, v, ix))	4,035,568
Repayment of lease liabilities	(32,555)	(40,922)
Net cash provided by financing activities	5,931,173	9,259,126
Effect of foreign exchange rate changes on cash and cash equivalents	(10,053)	(26)
Net increase in cash and cash equivalents	2,251,909	3,718,482
Cash and cash equivalents at beginning of period	5,427,739	128,777
Cash and cash equivalents at end of period	7,679,648	3,847,259
Supplementary disclosure of cash flow information:
Cash received as interest	210,090	40,636
Cash paid for taxes	269,007
Non-cash financing and investing activities
Derivative liability converted to equity		290,569
Right of use assets obtained in exchange for lease liabilities	181,779
Early termination of office lease (Note 4c)	$ (88,562)

Nature of Operations and Going

Nature of Operations and Going Concern	9 Months Ended
	Jul. 31, 2024
Nature of Operations and Going Concern [Abstract]
Nature of Operations and Going Concern	1. Nature of Operations and Going Concern a. Clearmind Medicine Inc. (the “Company”) was incorporated in the province of British Columbia on July 18, 2017. The Company is a clinical pharmaceutical company currently engaged in phase I/IIa clinical trials of novel psychedelic medicines that have been developed to solve widespread, yet under-served, health problems. The Company’s head office is located at Suite 101 -1220 West 6 th On November 14, 2022, the Company completed a listing on the Nasdaq Capital Market (“Nasdaq”). The Company trades under the symbol “CMND” on the Nasdaq and on the Frankfurt Stock Exchange, (FSE), under the symbol “CWY”. The Company was listed on the Canadian Securities Exchange (“CSE”) in Toronto until March 14, 2024. Following approval for a voluntary delisting, the Company no longer trades on the CSE but remains a reporting issuer in Canada. On January 16, 2024, the Company completed a registered direct and private placement for aggregate gross proceeds of $2.40 million. See note 6(c)(iii). b. Going concern These condensed interim consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. For the nine months ended July 31, 2024, the Company has not generated any revenues and has negative cash flows from operations of $3,781,514. As of July 31, 2024, the Company has an accumulated deficit of $23,137,997. The continued operations of the Company are dependent on its ability to generate future cash flows or obtain additional financing through debt or equity. Management is of the opinion that sufficient working capital will be obtained from external financing to meet the Company’s liabilities and commitments as they become due, although there is a risk that additional financing will not be available on a timely basis or on terms acceptable to the Company. These factors raise substantial doubt on the Company’s ability to continue as a going concern. These condensed interim consolidated financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern. c. Reverse share split On November 28, 2023, the Company’s Board of Directors (the “Board”) approved a 1-for-30 reverse split of its issued and outstanding common shares, effective as of November 28, 2023, pursuant to which holders of the Company’s common shares received 0.0333 of a common share for every one common share then held. All issued and outstanding common shares or instruments convertible into common shares contained in these financial statements have been retroactively adjusted to reflect the reverse share split for all periods presented, unless explicitly stated otherwise. d. On October 7, 2023, an unprecedented attack was launched against Israel by terrorists from the Hamas terrorist organization that infiltrated Israel’s southern border from the Gaza Strip and in other areas within the State of Israel attacking civilians and military targets while simultaneously launching extensive rocket attacks on the Israeli population, which led to the declaration of the ‘Iron Swords’ War (the “War”). The War is on-going as of the issuance date of these financial statements. The Company’s clinical trials, the laboratory that supports such clinical trials and the Contract Research Organization (CRO) are based in Israel. The extent to which the War may impact the Company’s financial condition, results of operations, or liquidity is uncertain, and as of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or an adjustment to the carrying value of the Company’s assets or liabilities as of July 31, 2024.

Material Accounting Policy Info

Material Accounting Policy Information	9 Months Ended
	Jul. 31, 2024
Material Accounting Policy Information [Abstract]
Material Accounting Policy Information	2. Material Accounting Policy Information a. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) on a going concern basis. These condensed interim consolidated financial statements include the accounts of the Company and its 100% owned subsidiaries, Clearmindmed Ltd. and Clearmind Labs Corp. (inactive). All inter-company balances and transactions have been eliminated on consolidation. These condensed interim consolidated financial statements have been prepared on a historical cost basis, except for financial assets and liabilities (including derivatives) which are presented at fair value through profit or loss (“FVTPL”), and are presented in United States dollars, which is the Company’s functional currency. b. Unaudited Interim Financial Information Certain information and footnote disclosures normally included in financial statements prepared in accordance with IFRS have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed interim consolidated financial statements should be read in conjunction with the audited financial statements as of and for the year ended October 31, 2023 and the notes thereto (the “2023 Annual Report”). The condensed interim consolidated financial statements have been prepared on the same basis as the 2023 Annual Report. In the opinion of the Company’s management, these condensed interim consolidated financial statements contain all adjustments that are necessary to present fairly the Company’s financial position and results of operations for the interim periods presented. The results for the nine months ended July 31, 2024 are not necessarily indicative of the results for the year ending October 31, 2024, or for any future period. As of July 31, 2024, there have been no material changes in the Company’s significant accounting policies from those that were disclosed in the 2023 Annual Report except for the following: Amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2 Making Materiality Judgements—Disclosure of Accounting Policies The Company has adopted the amendments to IAS 1 for the first time in the current year. The amendments change the requirements in IAS 1 with regard to disclosure of accounting policies. The amendments replace all instances of the term ‘significant accounting policies’ with ‘material accounting policy information’. Accounting policy information is material if, when considered together with other information included in an entity’s financial statements, it can reasonably be expected to influence decisions that the primary users of general purpose financial statements make on the basis of those financial statements. The supporting paragraphs in IAS 1 are also amended to clarify that accounting policy information that relates to immaterial transactions, other events or conditions that are immaterial and need not be disclosed. Accounting policy information may be material because of the nature of the related transactions, other events or conditions, even if the amounts are immaterial. However, not all accounting policy information relating to material transactions, other events or conditions is itself material. c. Significant Accounting Estimates and Judgments The preparation of consolidated financial statements in accordance with IFRS requires management to make judgments, estimates, and assumptions that affect the application of policies and reported amounts of assets, liabilities, income, and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Significant Estimates Share-based Compensation Fair values are determined using the Black-Scholes option pricing model. Estimating fair value requires determining the most appropriate valuation model for a grant of equity instruments, which is dependent on the terms and conditions of the grant. Option-pricing models require the use of highly subjective estimates and assumptions including the expected stock price volatility. Changes in the underlying assumptions can materially affect the fair value estimates and, therefore, existing models do not necessarily provide reliable measurement of the fair value of the Company’s stock options. Warrant Liability The Company analyses warrants issued to determine whether they meet the classification as liabilities or equity. Derivative warrant liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations. The Company uses a fair valuation specialist to estimate the value of these instruments using the binomial pricing model. The key assumptions used in the models are the expected future volatility in the price of the Company’s shares, the expected life of the warrants, the risk-free interest rate and the probability of any future adjustment event. Significant Judgments The critical judgments that the Company’s management has made in the process of applying the Company’s accounting policies that have the most significant effect on the amounts recognized in the Company’s consolidated financial statements are as follows: Going Concern The application of the going concern assumption requires management to take into account all available information about the future, which is at least but not limited to, 12 months from the end of the reporting period. The Company is aware that material uncertainties related to events or conditions raise substantial doubt upon the Company’s ability to continue as a going concern.

Short-term Investment

Short-term Investment	9 Months Ended
	Jul. 31, 2024
Short-term Investment [Abstract]
Short-term Investment	3. Short-term Investment Pursuant to the Share Exchange Agreement with XYLO TECHNOLOGIES LTD. (formerly Medigus Ltd.) (“XYLO”), on February 14, 2022, the Company received 27,778 ordinary shares of XYLO. The investment cost of the share was $501,938. During the nine months ended July 31, 2024, the Company sold all its remaining shares of XYLO, for total proceeds of $78,500 and recorded a net realized loss of $7,612. October 31, Disposals Net realized July 31, XYLO – Shares $ 86,112 $ 78,500 $ (7,612 ) $ – October 31, Additions Unrealized October 31, XYLO – Shares $ 193,750 $ – $ (107,638 ) $ 86,112

Related Party Transactions

Related Party Transactions	9 Months Ended
	Jul. 31, 2024
Related Party Transactions [Abstract]
Related Party Transactions	4. Related Party Transactions a. Compensation to key management personnel (i) The compensation to key management personnel for services they provide to the Company is as follows: Three months Three months ended Nine months Nine months July 31, July 31, July 31, July 31, 2024 2023 2024 2023 Officers: Consulting fees $ 86,792 $ 98,167 $ 335,066 $ 318,668 Share based compensation 103,977 31,709 251,717 107,089 $ 190,769 $ 129,876 $ 586,783 $ 425,757 Directors: Directors’ fees $ 58,538 $ 41,022 $ 184,063 $ 121,998 Share based compensation 101,157 28,558 310,069 106,682 $ 159,695 $ 69,580 $ 494,132 $ 228,680 (ii) Balances with related parties July 31, October 31, 2024 2023 Amounts owed to officers $ 29,625 $ 29,666 Amounts owed to directors 18,952 12,767 $ 48,577 $ 42,433 b. On March 7, 2022, the Company signed an agreement with SciSparc Ltd (“SciSparc”), pursuant to which the Company and SciSparc agreed to cooperate in conducting a feasibility study using certain molecules developed by each party (the “Cooperation Agreement”). Certain of the Company’s officers and directors currently operate, manage or are engaged as officers and/or directors of SciSparc. In June 2023, the Company entered into a research agreement with the Hebrew University of Jerusalem to evaluate SciSparc’s and the Company’s combination treatment for obesity and metabolic syndrome. To date, the collaboration has resulted in the filing of nine patent applications. To the extent the parties determine to proceed to a commercial cooperation, they may enter into a joint venture by the parties share the economics and rights on a 50%-50% basis. To date, no determination has been made to pursue the joint venture as the development of the project remains at a very early stage. For the three and nine months ended July 31, 2024, the Company incurred research and development expenses conducted within the framework of the Cooperation Agreement in the amount of $4,080 and $26,888, respectively (three and nine months ended July 31, 2023- $126,661 and $126,661, respectively). As of July 31, 2024, $108,597 is owed to the Company by SciSparc (October 31, 2023- $136,002). c. On December 25, 2023, the Company entered into an agreement with SciSparc for the lease of office space in Tel Aviv, Israel, having a total area of approximately 240 square meters. The Company occupies approximately 120 square meters of the space for its offices. The Company’s base rent was ILS 23,300 per month ($6,500) during the term of the lease. The lease liability was discounted using the Company’s estimated incremental borrowing rate of 10%. On March 31, 2024, the Company and SciSparc agreed to terminate the lease agreement prior to the initial term of the lease. As a result, the Company paid early termination fees of approximately $13,000 and paid approximately $3,000 to a broker. The loss upon early termination related to this transaction was recorded as other expenses within the Condensed Interim Consolidated Statements of Operations and Comprehensive Loss. On June 13, 2024, the Company entered into an agreement with SciSparc for the lease of office space in Tel Aviv, Israel, having a total area of approximately 386 square meters. The Company occupies approximately 193 square meters of the space for its offices. The rental period is from April 1, 2024 to March 31, 2026. The Company’s base rent was ILS 12,500 per month ($3,400) during the term of the lease. The lease liability was discounted using the Company’s estimated incremental borrowing rate of 10%.

Derivative Warrant Liabilities

Derivative Warrant Liabilities	9 Months Ended
	Jul. 31, 2024
Derivative Warrant Liabilities [Abstract]
Derivative warrant liabilities	5. Derivative warrant liabilities a. On April 6, 2023, the Company issued 4,505,718 warrants in connection with its April 2023 Public Offering (“April 2023 Warrants”). The warrant includes a cashless exercise provision and repricing adjustments for offerings at a price lower than the existing exercise price of the warrants, stock splits, reclassifications, subdivisions, and other similar transactions (“April 2023 Warrant Adjustments”) and therefore, these warrants were recorded at their fair value as a derivative liability and the time of the grant and are revalued at the end of each reporting period. The number of warrants do not change, however, the number of warrant shares issued may change, subject to the adjustment noted above. On January 21, 2024, following the January 2024 Public Offering, which included the offering of common shares at a price lower than the exercise price of the April 2023 Warrants, the exercise price of the April 2023 Warrants was reduced to $1.077, and each April 2023 Warrant became exercisable into 0.724 common shares of the Company. For further details of the ratio of warrant shares issuable and outstanding in relation to the April 2023 Warrants, see detailed table in note 7. During the period between November 29, 2023 and December 5, 2023, 2,729,394 April 2023 Warrants were exercised into 652,521 common shares. During the period between March 8, 2024 and March 22, 2024, 27,793 April 2023 Warrants were exercised into 20,245 common shares. On June 28, 2024, 156,098 April 2023 Warrants were exercised into 112,975 common shares. b. On September 18, 2023, the Company issued 7,500,000 warrants in connection with its September 2023 Public Offering (“September 2023 Warrants”). The warrant includes a cashless exercise provision and repricing adjustments for offerings at a price lower than the existing exercise price of the warrants, stock splits, reclassifications, subdivisions, and other similar transactions (“September 2023 Warrant Adjustments”) and therefore, these warrants were recorded at their fair value as a derivative liability and the time of the grant and are revalued at the end of each reporting period. The number of warrants do not change, however, the number of warrant shares issued may change, subject to the adjustment noted above. On January 21, 2024, following the January 2024 Public Offering, which included the offering of common shares at a price lower than the exercise price of the September 2023 Warrants, the exercise price of the September 2023 Warrants was reduced to $1.077, and each September 2023 Warrant became exercisable into 0.288 common shares of the Company. For further details of the ratio of warrant shares issuable and outstanding in relation to the September 2023 Warrants, see detailed table in note 7. During the period between November 29, 2023 and December 5, 2023, 4,602,916 September 2023 Warrants were exercised into 409,667 common shares. During the period between February 23, 2024 and March 22, 2024, 281,910 September 2023 Warrants were exercised into 81,469 common shares. On June 28, 2024, 182,144 September 2023 Warrants were exercised into 54,877 common shares. c. On January 16, 2024, the Company issued 1,500,000 warrants with an exercise price of $1.60 per warrant in connection with its January 2024 Public Offering (“January 2024 Warrants”). Each warrant includes a cashless exercise provision and repricing adjustments for offerings at a price lower than the existing exercise price of the warrants, stock splits, reclassifications, subdivisions, and other similar transactions (“January 2024 Warrant Adjustments”) and therefore, these warrants were recorded at their fair value as a derivative liability at the time of the grant and are revalued at the end of each reporting period. On February 23, 2024, 30,200 January 2024 Warrants were exercised into 30,200 common shares. During the period between June 20, 2024 and July 16, 2024, 138,320 January 2024 Warrants were exercised into 138,320 common shares. d. During the three and nine months ended July 31, 2024, the Company recorded a loss on the revaluation of the total derivative warrant liabilities of $643,225 and $83,080, respectively, in the Condensed Interim Consolidated Statements of Operations and Comprehensive Loss. e. The binomial model was used to measure the derivative warrant liability with the following assumptions: July 31, Share Price $1.66 Exercise Price $1.077 – $1.60 Expected life 3.68 – 4.46 years Risk-free interest rate 4.00 – 4.07% Dividend yield 0.00% Expected volatility 149.52 – 152.96% f. The following table presents the changes in the derivative warrant liability during the period: Balance as of November 1, 2022 $ - Issuance of April 2023 Warrants 1,771,208 Issuance of September 2023 Warrants 923,225 Exercise of warrants (574,040 ) Change in fair value of warrants 2,189,986 Balance as of October 31, 2023 $ 4,310,379 Issuance of January 2024 Warrants 480,004 Exercise of warrants (559,240 ) Change in fair value of warrants 83,080 Balance as of July 31, 2024 $ 4,314,223

Share Capital

Share Capital	9 Months Ended
	Jul. 31, 2024
Share Capital [Abstract]
Share Capital	6. Share Capital a. The Company’s authorized share capital is unlimited common shares without par value share. On November 28, 2023, the Company effected a 1-for-30 share consolidation. All share amounts and instruments convertible into common shares prior to the date of the reverse share split have been retroactively restated for all periods presented. b. As of July 31, 2024, the number of common shares issued and outstanding was 3,979,243 (October 31, 2023 – 607,337). c. Share transactions during the nine months ended July 31, 2024: (i) On November 6, 2023, 45 common shares with a fair value of $117 were issued to providers of investor services in payment of services. (ii) Between November 29, 2023 and December 5, 2023, April 2023 Warrants and September 2023 Warrants were exercised into 1,062,188 shares, resulting in gross proceeds of $3,498,032. (iii) On January 16, 2024, the Company completed a registered direct offering and concurrent private placement of (i) 1,468,000 Common Shares, (ii) 32,000 pre-funded warrants to purchase 32,000 Common Shares and (iii) 1,500,000 unregistered common warrants to purchase 1,500,000 Common Shares. The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per Common Share and will not expire until exercised in full. The unregistered common warrants have an exercise price of $1.60 per Common Share (after giving effect to adjustments and subject to further adjustments as set forth therein), are immediately exercisable, and expire five years from the date of issuance. These warrants include a cashless exercise provision and repricing provisions, under certain circumstances (“the January 2024 Offering”). The gross proceeds from the January 2024 Offering were approximately $2.4 million before deducting estimated offering expenses. Net proceeds from the offering were $1,824,773. On January 17, 2024, the pre-funded warrants were exercised. (iv) On February 19, 2024, 44 common shares with a fair value of $68 were issued to providers of investor services in payment of services. (v) During the period between February 23, 2024 and March 2, 2024, April 2023 Warrants, September 2023 Warrants and January 2024 Warrants were exercised into 131,914 shares, for gross proceeds of $157,918. (vi) On April 3, 2024, 9,000 common shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $11,935 at the time of issuance. (vii) On May 9, 2024, 88 common shares with a fair value of $127 were issued to providers of investor services in payment of services. (viii) On June 17, 2024, 162,970 common shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $243,003 at the time of issuance. (ix) During the period between June 20, 2024 and July 16, 2024, April 2023 Warrants, September 2023 Warrants and January 2024 Warrants were exercised into 306,172 shares, for gross proceeds of $402,206. (ix) On July 4, 2024, 64,617 common shares with a fair value of $103,387 were issued to providers of investor services in payment of services. (xi) During the period between July 4, 2024 and July 8, 2024, 134,868 common shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $256,252 at the time of issuance. d. Share transactions during the nine months ended July 31, 2023: (i) On November 14, 2022, the Company completed an underwritten public offering of 38,462 common shares at a price to the public of $195.00 per share, for aggregate gross proceeds of $7.5 million, prior to deducting underwriting discounts and offering expenses. The offering closed on November 17, 2022. Net proceeds from the offering were $6,363,906. In addition, the Company granted Aegis Capital Corp. (“Aegis”), who acted as the underwriters for the deal, a 45-day option to purchase up to 5,769 additional common shares, equal to 15% of the number of common shares sold in the offering solely to cover over-allotments, if any (“Over-Allotment”). The public purchase price per additional common share would have been $195.00 per share. The Over-Allotment was not exercised. Aegis received 1,923 underwriter warrants, (the “Underwriter Warrants”) each such Underwriter Warrant entitling the agents to receive one common share upon payment of $243.75 per share, exercisable six months after the commencement of sales of this offering and expiring on a date which is no more than five years after the commencement of sales of the offering. The fair value of the Underwriter Warrants of $337,579 were accounted for as an issuance cost within the share-based payment reserve. The fair value of the Underwriter Warrants was estimated using the Black-Scholes option pricing model assuming no expected dividends or forfeitures and the following weighted average assumptions: Risk-free interest rate 1.43 % Expected life (in years) 5 Expected volatility 150 % In connection with the offering, the Company’s common shares were approved for listing on the Nasdaq and began trading on the Nasdaq (in addition to the CSE) under the symbol “CMND” on November 15, 2022. Following the public offering and pursuant to the XYLO SPA, XYLO was entitled to receive 1,494 common shares and 75 warrants pursuant to an anti-dilution clause included in the agreement signed between the Company and XYLO on June 29, 2022. The anti-dilution feature was recorded as a derivative liability as of October 31, 2022. (ii) On January 16, 2023, 161 common shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $39,975 at the time of issuance. On February 22, 2023, 400 common shares were issued in respect of fully vested RSU’s that had been fully vested. The RSU’s had a fair value of $110,096 at the time of issuance. (iii) On April 6, 2023, the Company completed an underwritten public offering of 103,249 common shares at a price to the public of $23.40 per share and pre-funded warrants to purchase 46,942 common shares at a price to the public of $23.37 per pre-funded warrant (“Pre-Funded Warrants”), for aggregate gross proceeds of $3.5 million (the “April 2023 Public Offering”). The Pre-Funded Warrants were exercisable at $0.03 into one common share, and all the Pre-Funded Warrants were exercised by April 30, 2023. In addition, each April 2023 Public Offering shareholder and each Pre-Funded Warrant holder received a common warrant, which was immediately exercisable, will expire five years from the date of issuance and have an exercise price of $23.40 per common share (“April 2023 Public Offering Warrant”). The April 2023 Public Offering warrants include a cashless exercise provision and repricing provisions under certain circumstances, that also includes a potential change in the number of shares to be issued for each warrant depending on the change in the exercise price of the warrant. Net proceeds from the offering were $2,936,079. (iv) On May 23, 2023, 239 common shares with a fair value of $27,965 were issued to consultants and 1,494 common shares with a fair value of $110,000 were issued to providers of investor services in respect of services. (v) On June 1, 2023, 245 common shares were issued in respect of RSU’s that had been fully vested. The RSU’s had a fair value of $48,194 at the time of issuance. (vi) On July 10, 2023, 597 common shares with a fair value of $10,000 were issued to providers of investor services in respect of services.

Warrants

Warrants	9 Months Ended
	Jul. 31, 2024
Warrants [Abstract]
Warrants	7. Warrants The following table summarizes the changes in the Company’s warrants: Number of Historic weighted Balance, October 31, 2022 19,763 576.66 Issuance of underwriter warrants 1,923 243.75 Issuance of April 2023 warrants (*) 4,505,718 5.124 Issuance of September 2023 warrants (**) 7,500,000 9.00 Issuance of XYLO warrants 75 1,297.67 Expiration of warrants (11,430 ) 922.98 Exercise of warrants (784,584 ) 5.124 Balance, October 31, 2023 11,231,465 $ 7.90 Number of shares to be issued from the exercise of these warrants 826,781 Balance, October 31, 2023 11,231,465 $ 7.90 Issuance of January 2024 warrants (Note 5c) 1,500,000 1.60 Exercise of warrants (8,148,955 ) 2.69 Expiration of warrants (8,333 ) 98.43 Balance, July 31, 2024 4,574,177 $ 1.56 Number of shares to be issued from the exercise of these warrants 2,618,903 (*) These warrants convert into 584,545 shares. (**) These warrants convert into 700,880 shares. As of July 31, 2024, the following warrants were outstanding: Number of Number of shares Exercise price per Exercise price per Expiry date 1,923 1,923 C$ 336.59 $ 243.75 November 17, 2027 807,669 584,545 $ 1.077 $ 1.077 April 5, 2028 75 75 C$ 1,800 $ 1,303.49 November 23, 2024 2,433,030 700,880 $ 1.077 $ 1.077 September 17, 2028 1,331,480 1,331,480 $ 1.60 $ 1.60 January 15, 2029 4,574,177 2,618,903

Stock Options

Stock Options	9 Months Ended
	Jul. 31, 2024
Stock Options [Abstract]
Stock Options	8. Stock Options (a) On November 14, 2023, the shareholders of the Company approved the Omnibus Equity Incentive Plan, or the Omnibus Plan. Pursuant to the Omnibus Plan, the Company is authorized to grant options or restricted share units (“RSUs) to officers, directors, employees and consultants enabling them to acquire, together with” Options”, “Awards” or “Stock Options” as defined, up to 20% of the Company’s issued and outstanding Common Shares (after taking into account existing awards from the Company’s 2021 stock option plan). The Awards can be granted for a maximum of 10 years and vest as determined by the Board. The maximum number of common shares reserved for issuance in any 12-month period to a related party consultant may not exceed 5% of the issued and outstanding common shares at the date of the grant (and may not exceed 15% in total, to all related parties). The maximum number of common shares reserved for issuance in any 12-month period to any investor relations service provider may not exceed 2% of the issued and outstanding common shares at the date of the grant. (b) The following table summarizes the changes in the Company’s stock options for the periods ended July 31, 2024 and October 31, 2023: Number of options Weighted average exercise price (C$) Weighted average exercise price (USD$) Outstanding, October 31, 2022 5,254 C$ 613.5 $ 450.64 Granted 334 442.22 318.81 Outstanding, October 31, 2023 5,588 C$ 603.12 $ 434.81 Expired (67 ) 720.00 533.14 Outstanding, July 31, 2024 5,521 C$ 601.70 $ 435.73 Exercisable, July 31, 2024 5,160 C$ 603.20 $ 436.82 (c) Additional information regarding stock options outstanding as of July 31, 2024, is as follows: Outstanding Exercisable Number of Weighted Weighted Weighted Number of Weighted Weighted 533 1.82 C$ 166.50 $ 120.57 533 C$ 166.50 $ 120.57 978 7.51 504.00 364.98 858 504.00 364.98 1,166 1.82 675.00 488.81 1,166 675.00 488.81 200 4.75 702.00 508.36 192 702.00 508.36 133 2.14 747.00 540.95 133 747.00 540.95 422 7.36 612.00 443.19 422 612.00 443.19 1,044 7.51 720.00 521.40 870 720.00 521.40 667 1.92 756.00 547.47 667 756.00 547.47 111 7.36 900.00 651.75 102 900.00 651.75 61 8.82 315.00 228.11 53 315.00 228.11 156 8.91 504.00 364.98 143 504.00 364.98 50 8.94 32.31 23.40 21 32.31 23.40 5,521 4.91 C$ 601.70 $ 435.73 5,160 C$ 603.20 $ 436.82 The fair value for stock options previously granted to certain consultants for ongoing services measured during the period have been estimated using the Black-Scholes option pricing model assuming no expected dividends or forfeitures and the following weighted average assumptions: Nine months Nine months Risk-free interest rate 4.05 % 3.83 % Expected life (in years) 4.86 5.86 Expected volatility 121.10%-133.14 % 111%-116 % d. The portion of the total fair value of stock options expensed during the three and nine months ended July 31, 2024, were $14,879 and $71,793, respectively (2023 - $59,513 and $181,448, respectively) which was recorded in share-based compensation expense.

Restricted Share Units

Restricted Share Units	9 Months Ended
	Jul. 31, 2024
Restricted Share Units [Abstract]
Restricted Share Units	9. Restricted Share Units The following table summarizes the continuity of RSUs: Number of Weighted Weighted Balance, October 31, 2022 – $ – $ – Granted 2,200 55.97 41.46 Vested (2,200 ) 55.97 41.46 Balance, October 31, 2023 – $ – $ – Granted (i) 476,189 1.85 1.34 Vested (457,981 ) 1.86 1.37 Balance, July 31, 2024 18,208 $ 1.52 $ 1.10 (i) During the nine months ended July 31, 2024, the Company issued 476,189 RSU’s to consultants, directors and officers. 457,981 RSU’s vested with a fair value of $629,720 (2023-$90,598).

Financial Instruments and Risk

Financial Instruments and Risk Management	9 Months Ended
	Jul. 31, 2024
Financial Instruments and Risk Management [Abstract]
Financial Instruments and Risk Management	10. Financial Instruments and Risk Management a. Assets and liabilities measured at fair value on a recurring basis were presented in the Company’s statement of financial position as of July 31, 2024, as follows: Fair Value Measurements Using Quoted prices Significant Significant Balance Derivative warrants liability $ – $ – $ 4,314,223 $ 4,314,223 Assets and liabilities measured at fair value on a recurring basis were presented in the Company’s statement of financial position as of October 31, 2023, as follows: Fair Value Measurements Using Quoted prices Significant Significant Balance Short-term investment $ 86,112 $ – $ – $ 86,112 Derivative warrants liability – – 4,310,379 4,310,379 The fair value of other assets and liabilities, which include cash, amounts receivable, accounts payable and accrued liabilities, and amounts due to related parties, approximate their carrying values due to the relatively short-term maturity of these instruments. b. Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash. The Company limits its exposure to credit loss by placing its cash with high credit quality financial institutions. The carrying amount of financial assets represents the maximum credit exposure. c. Foreign Exchange Rate Risk Foreign currency risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate due to changes in foreign exchange rates. The Company is exposed to foreign currency risk to the extent that monetary assets and liabilities are denominated in a foreign currency. The Company’s subsidiary operates in Israel and has certain monetary financial instruments denominated in New Israeli Shekel and CAD. The Company has not entered into foreign exchange rate contracts to mitigate this risk. The following table indicates the impact of foreign currency exchange risk on net working capital as of July 31, 2024. The table below also provides a sensitivity analysis of a 10% strengthening of the foreign currency against functional currencies identified which would have increased (decreased) the Company’s net loss by the amounts shown in the table below. A 10% weakening of the foreign currency against the functional currencies would have had the equal but opposite effect as of July 31, 2024. Cash and cash equivalents $ 75,440 Other receivables 62,380 Accounts payable and accrued liabilities (105,839 ) Due to related parties (38,577 ) Total foreign currency financial assets and liabilities $ (6,596 ) Impact of a 10% strengthening or weakening of foreign exchange rate $ (660 ) d. Interest Rate Risk Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to significant interest rate risk as it does not have any liabilities with variable rates. e. Liquidity Risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company’s objective to managing liquidity risk is to ensure that it has sufficient liquidity available to meet its liabilities when due. The Company relies on raising debt or equity financing in a timely manner. The following amounts are the contractual maturities of financial liabilities as of July 31, 2024 and October 31, 2023: July 31, 2024 Total Within Within Accounts payable and accrued liabilities $ 276,744 $ 276,744 $ – Due to related parties 48,577 48,577 – Lease liability 60,898 35,320 25,578 $ 386,219 $ 360,641 $ 25,578 October 31, 2023 Total Within Within Accounts payable and accrued liabilities $ 617,004 $ 617,004 $ – Due to related parties 42,433 42,433 – $ 659,437 $ 659,437 $ –

Capital Management

Capital Management	9 Months Ended
	Jul. 31, 2024
Capital Management [Abstract]
Capital Management	11. Capital Management The Company manages its capital to maintain its ability to continue as a going concern and to provide returns to shareholders and benefits to other stakeholders. The capital structure of the Company consists of cash and equity comprised of issued share capital, RSU reserve, warrants reserve, and options reserve. The Company manages its capital structure and makes adjustments to it in light of economic conditions. The Company, upon approval from its Board, will balance its overall capital structure through new share issuances or by undertaking other activities as deemed appropriate under the specific circumstances. The Company is not subject to externally imposed capital requirements and the Company’s overall strategy with respect to capital risk management remains unchanged from the nine months ended July 31, 2024.

Segmented Information

Segmented Information	9 Months Ended
	Jul. 31, 2024
Segmented Information [Abstract]
Segmented Information	12. Segmented Information As of July 31, 2024, the Company has one operating segment, being the research and development of novel psychedelic medicine, which takes place primarily in Israel.

Commitments

Commitments	9 Months Ended
	Jul. 31, 2024
Commitments [Abstract]
Commitments	13. Commitments a. On January 15, 2024, the Company signed a long-term licensing agreement with the research & development company of Bar-Ilan University (“BIRAD”), a leading Israeli research center. The licensing agreement refers to the Company’s dedicated treatment for cocaine addiction which previously indicated a significant decrease in cocaine craving. Under this agreement, the Company received a worldwide exclusive license and will pay BIRAD certain milestone payments upon commerciality of the product and royalties of 2.5% for a period of 15 years following the first commercial sale. b. On March 19, 2024, the Company signed an exclusive patent licensing agreement with Yissum research development company of the Hebrew University of Jerusalem. This agreement provides Clearmind with exclusive global rights to further develop, manufacture, and commercialize innovative compounds invented by Professors Rami Yaka, Ahmed Masaewa and Avi Priel from the Hebrew University. The Company will pay Yissum, royalties of 3% on sales. In addition, the Company will pay an annual license fee of $25,000 for seven years, after which the license fee will increase to $35,000 for three years, and $50,000 for every year thereafter. Finally, the Company will pay Yissum $400,000 upon the first patient enrolled in a Phase III Clinical Trial and $600,000 upon first commercial sale in the US or EU. c. On Marh 30, 2024, the Company signed an exclusive licensing agreement with Yissum. Under the terms of the agreement, Clearmind receives exclusive worldwide rights to develop, research, manufacture, market, and commercialize products derived from a patent-pending synthesis of psychedelic compounds, enriching the company’s innovative portfolio in addiction and mental health treatments. The Company will pay Yissum royalties of 3% on sales. In addition, the Company will pay an annual license fee of $25,000 for seven years, after which the license fee will increase to $35,000 for three years, and $50,000 for every year thereafter. Finally, the Company will pay Yissum $400,000 upon the first patient enrolled in a Phase III Clinical Trial and $600,000 upon first commercial sale in the US or EU. d. Respect to the Company’s lease commitment, refer to Note 4c.

Subsequent Events

Subsequent Events	9 Months Ended
	Jul. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events On August 12, 2024, April 2023 Warrants and September 2023 Warrants were exercised into 69,592 shares, for gross proceeds of $74,999.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Jul. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	a. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) on a going concern basis. These condensed interim consolidated financial statements include the accounts of the Company and its 100% owned subsidiaries, Clearmindmed Ltd. and Clearmind Labs Corp. (inactive). All inter-company balances and transactions have been eliminated on consolidation. These condensed interim consolidated financial statements have been prepared on a historical cost basis, except for financial assets and liabilities (including derivatives) which are presented at fair value through profit or loss (“FVTPL”), and are presented in United States dollars, which is the Company’s functional currency.
Unaudited Interim Financial Information	b. Unaudited Interim Financial Information Certain information and footnote disclosures normally included in financial statements prepared in accordance with IFRS have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed interim consolidated financial statements should be read in conjunction with the audited financial statements as of and for the year ended October 31, 2023 and the notes thereto (the “2023 Annual Report”). The condensed interim consolidated financial statements have been prepared on the same basis as the 2023 Annual Report. In the opinion of the Company’s management, these condensed interim consolidated financial statements contain all adjustments that are necessary to present fairly the Company’s financial position and results of operations for the interim periods presented. The results for the nine months ended July 31, 2024 are not necessarily indicative of the results for the year ending October 31, 2024, or for any future period. As of July 31, 2024, there have been no material changes in the Company’s significant accounting policies from those that were disclosed in the 2023 Annual Report except for the following: Amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2 Making Materiality Judgements—Disclosure of Accounting Policies The Company has adopted the amendments to IAS 1 for the first time in the current year. The amendments change the requirements in IAS 1 with regard to disclosure of accounting policies. The amendments replace all instances of the term ‘significant accounting policies’ with ‘material accounting policy information’. Accounting policy information is material if, when considered together with other information included in an entity’s financial statements, it can reasonably be expected to influence decisions that the primary users of general purpose financial statements make on the basis of those financial statements. The supporting paragraphs in IAS 1 are also amended to clarify that accounting policy information that relates to immaterial transactions, other events or conditions that are immaterial and need not be disclosed. Accounting policy information may be material because of the nature of the related transactions, other events or conditions, even if the amounts are immaterial. However, not all accounting policy information relating to material transactions, other events or conditions is itself material.
Significant Accounting Estimates and Judgments	c. Significant Accounting Estimates and Judgments The preparation of consolidated financial statements in accordance with IFRS requires management to make judgments, estimates, and assumptions that affect the application of policies and reported amounts of assets, liabilities, income, and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Significant Estimates Share-based Compensation Fair values are determined using the Black-Scholes option pricing model. Estimating fair value requires determining the most appropriate valuation model for a grant of equity instruments, which is dependent on the terms and conditions of the grant. Option-pricing models require the use of highly subjective estimates and assumptions including the expected stock price volatility. Changes in the underlying assumptions can materially affect the fair value estimates and, therefore, existing models do not necessarily provide reliable measurement of the fair value of the Company’s stock options. Warrant Liability The Company analyses warrants issued to determine whether they meet the classification as liabilities or equity. Derivative warrant liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations. The Company uses a fair valuation specialist to estimate the value of these instruments using the binomial pricing model. The key assumptions used in the models are the expected future volatility in the price of the Company’s shares, the expected life of the warrants, the risk-free interest rate and the probability of any future adjustment event. Significant Judgments The critical judgments that the Company’s management has made in the process of applying the Company’s accounting policies that have the most significant effect on the amounts recognized in the Company’s consolidated financial statements are as follows: Going Concern The application of the going concern assumption requires management to take into account all available information about the future, which is at least but not limited to, 12 months from the end of the reporting period. The Company is aware that material uncertainties related to events or conditions raise substantial doubt upon the Company’s ability to continue as a going concern.

Short-term Investment (Tables)

Short-term Investment (Tables)	9 Months Ended
	Jul. 31, 2024
Short-term Investment [Abstract]
Schedule of Ordinary Shares of Medigus	During the nine months ended July 31, 2024, the Company sold all its remaining shares of XYLO, for total proceeds of $78,500 and recorded a net realized loss of $7,612. October 31, Disposals Net realized July 31, XYLO – Shares $ 86,112 $ 78,500 $ (7,612 ) $ – October 31, Additions Unrealized October 31, XYLO – Shares $ 193,750 $ – $ (107,638 ) $ 86,112

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Jul. 31, 2024
Related Party Transactions [Abstract]
Schedule of Key Management Personnel for Services	The compensation to key management personnel for services they provide to the Company is as follows: Three months Three months ended Nine months Nine months July 31, July 31, July 31, July 31, 2024 2023 2024 2023 Officers: Consulting fees $ 86,792 $ 98,167 $ 335,066 $ 318,668 Share based compensation 103,977 31,709 251,717 107,089 $ 190,769 $ 129,876 $ 586,783 $ 425,757 Directors: Directors’ fees $ 58,538 $ 41,022 $ 184,063 $ 121,998 Share based compensation 101,157 28,558 310,069 106,682 $ 159,695 $ 69,580 $ 494,132 $ 228,680
Schedule of Balances with Related Parties	Balances with related parties July 31, October 31, 2024 2023 Amounts owed to officers $ 29,625 $ 29,666 Amounts owed to directors 18,952 12,767 $ 48,577 $ 42,433

Derivative Warrant Liabilities

Derivative Warrant Liabilities (Tables)	9 Months Ended
	Jul. 31, 2024
Derivative Warrant Liabilities [Abstract]
Schedule of Binomial Model was used to Measure the Derivative Warrant Liability	The binomial model was used to measure the derivative warrant liability with the following assumptions: July 31, Share Price $1.66 Exercise Price $1.077 – $1.60 Expected life 3.68 – 4.46 years Risk-free interest rate 4.00 – 4.07% Dividend yield 0.00% Expected volatility 149.52 – 152.96%
Schedule of Changes in the Warrants Liability	The following table presents the changes in the derivative warrant liability during the period: Balance as of November 1, 2022 $ - Issuance of April 2023 Warrants 1,771,208 Issuance of September 2023 Warrants 923,225 Exercise of warrants (574,040 ) Change in fair value of warrants 2,189,986 Balance as of October 31, 2023 $ 4,310,379 Issuance of January 2024 Warrants 480,004 Exercise of warrants (559,240 ) Change in fair value of warrants 83,080 Balance as of July 31, 2024 $ 4,314,223

Share Capital (Tables)

Share Capital (Tables)	9 Months Ended
	Jul. 31, 2024
Share Capital [Abstract]
Schedule of the Fair Value of Underwriters Warrants	The fair value of the Underwriter Warrants was estimated using the Black-Scholes option pricing model assuming no expected dividends or forfeitures and the following weighted average assumptions: Risk-free interest rate 1.43 % Expected life (in years) 5 Expected volatility 150 %

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Jul. 31, 2024
Warrants [Abstract]
Schedule of Warrants	The following table summarizes the changes in the Company’s warrants: Number of Historic weighted Balance, October 31, 2022 19,763 576.66 Issuance of underwriter warrants 1,923 243.75 Issuance of April 2023 warrants (*) 4,505,718 5.124 Issuance of September 2023 warrants (**) 7,500,000 9.00 Issuance of XYLO warrants 75 1,297.67 Expiration of warrants (11,430 ) 922.98 Exercise of warrants (784,584 ) 5.124 Balance, October 31, 2023 11,231,465 $ 7.90 Number of shares to be issued from the exercise of these warrants 826,781 Balance, October 31, 2023 11,231,465 $ 7.90 Issuance of January 2024 warrants (Note 5c) 1,500,000 1.60 Exercise of warrants (8,148,955 ) 2.69 Expiration of warrants (8,333 ) 98.43 Balance, July 31, 2024 4,574,177 $ 1.56 Number of shares to be issued from the exercise of these warrants 2,618,903 (*) These warrants convert into 584,545 shares. (**) These warrants convert into 700,880 shares.
Schedule of Warrants Outstanding	As of July 31, 2024, the following warrants were outstanding: Number of Number of shares Exercise price per Exercise price per Expiry date 1,923 1,923 C$ 336.59 $ 243.75 November 17, 2027 807,669 584,545 $ 1.077 $ 1.077 April 5, 2028 75 75 C$ 1,800 $ 1,303.49 November 23, 2024 2,433,030 700,880 $ 1.077 $ 1.077 September 17, 2028 1,331,480 1,331,480 $ 1.60 $ 1.60 January 15, 2029 4,574,177 2,618,903

Stock Options (Tables)

Stock Options (Tables)	9 Months Ended
	Jul. 31, 2024
Stock Options [Abstract]
Schedule of Changes in Stock Options	The following table summarizes the changes in the Company’s stock options for the periods ended July 31, 2024 and October 31, 2023: Number of options Weighted average exercise price (C$) Weighted average exercise price (USD$) Outstanding, October 31, 2022 5,254 C$ 613.5 $ 450.64 Granted 334 442.22 318.81 Outstanding, October 31, 2023 5,588 C$ 603.12 $ 434.81 Expired (67 ) 720.00 533.14 Outstanding, July 31, 2024 5,521 C$ 601.70 $ 435.73 Exercisable, July 31, 2024 5,160 C$ 603.20 $ 436.82
Schedule of Additional Information Regarding Stock Options Outstanding	Additional information regarding stock options outstanding as of July 31, 2024, is as follows: Outstanding Exercisable Number of Weighted Weighted Weighted Number of Weighted Weighted 533 1.82 C$ 166.50 $ 120.57 533 C$ 166.50 $ 120.57 978 7.51 504.00 364.98 858 504.00 364.98 1,166 1.82 675.00 488.81 1,166 675.00 488.81 200 4.75 702.00 508.36 192 702.00 508.36 133 2.14 747.00 540.95 133 747.00 540.95 422 7.36 612.00 443.19 422 612.00 443.19 1,044 7.51 720.00 521.40 870 720.00 521.40 667 1.92 756.00 547.47 667 756.00 547.47 111 7.36 900.00 651.75 102 900.00 651.75 61 8.82 315.00 228.11 53 315.00 228.11 156 8.91 504.00 364.98 143 504.00 364.98 50 8.94 32.31 23.40 21 32.31 23.40 5,521 4.91 C$ 601.70 $ 435.73 5,160 C$ 603.20 $ 436.82
Schedule of Fair Value of Stock Options	The fair value for stock options previously granted to certain consultants for ongoing services measured during the period have been estimated using the Black-Scholes option pricing model assuming no expected dividends or forfeitures and the following weighted average assumptions: Nine months Nine months Risk-free interest rate 4.05 % 3.83 % Expected life (in years) 4.86 5.86 Expected volatility 121.10%-133.14 % 111%-116 %

Restricted Share Units (Tables)

Restricted Share Units (Tables)	9 Months Ended
	Jul. 31, 2024
Restricted Share Units [Abstract]
Schedule of Continuity of RSUs	The following table summarizes the continuity of RSUs: Number of Weighted Weighted Balance, October 31, 2022 – $ – $ – Granted 2,200 55.97 41.46 Vested (2,200 ) 55.97 41.46 Balance, October 31, 2023 – $ – $ – Granted (i) 476,189 1.85 1.34 Vested (457,981 ) 1.86 1.37 Balance, July 31, 2024 18,208 $ 1.52 $ 1.10 (i) During the nine months ended July 31, 2024, the Company issued 476,189 RSU’s to consultants, directors and officers. 457,981 RSU’s vested with a fair value of $629,720 (2023-$90,598).

Financial Instruments and Ris_2

Financial Instruments and Risk Management (Tables)	9 Months Ended
	Jul. 31, 2024
Financial Instruments and Risk Management [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value	Assets and liabilities measured at fair value on a recurring basis were presented in the Company’s statement of financial position as of July 31, 2024, as follows: Fair Value Measurements Using Quoted prices Significant Significant Balance Derivative warrants liability $ – $ – $ 4,314,223 $ 4,314,223 Fair Value Measurements Using Quoted prices Significant Significant Balance Short-term investment $ 86,112 $ – $ – $ 86,112 Derivative warrants liability – – 4,310,379 4,310,379
Schedule of Foreign Currency Exchange Risk on Net Working Capital	A 10% weakening of the foreign currency against the functional currencies would have had the equal but opposite effect as of July 31, 2024. Cash and cash equivalents $ 75,440 Other receivables 62,380 Accounts payable and accrued liabilities (105,839 ) Due to related parties (38,577 ) Total foreign currency financial assets and liabilities $ (6,596 ) Impact of a 10% strengthening or weakening of foreign exchange rate $ (660 )
Schedule of Contractual Maturities of Financial Liabilities	The following amounts are the contractual maturities of financial liabilities as of July 31, 2024 and October 31, 2023: July 31, 2024 Total Within Within Accounts payable and accrued liabilities $ 276,744 $ 276,744 $ – Due to related parties 48,577 48,577 – Lease liability 60,898 35,320 25,578 $ 386,219 $ 360,641 $ 25,578 October 31, 2023 Total Within Within Accounts payable and accrued liabilities $ 617,004 $ 617,004 $ – Due to related parties 42,433 42,433 – $ 659,437 $ 659,437 $ –

Nature of Operations and Goin_2

Nature of Operations and Going Concern (Details) - USD ($)					9 Months Ended
	Jan. 16, 2024	Nov. 28, 2023	Apr. 06, 2023	Nov. 14, 2022	Jul. 31, 2024	Jul. 31, 2023	Oct. 31, 2023
Nature of Operations and Going Concern [Abstract]
Incorporation date					Jul. 18, 2017
Aggregate gross proceeds	$ 2,400,000		$ 3,500,000	$ 7,500,000
Cash flow from operations					$ (3,781,514)	$ (5,548,304)
Accumulated deficit					$ (23,137,997)		$ (18,768,063)
Reverse stock split, description		1-for-30 reverse split
Price per share (in Dollars per share)		$ 0.0333

Material Accounting Policy In_2

Material Accounting Policy Information (Details)	9 Months Ended
	Jul. 31, 2024
Material Accounting Policy Information [Abstract]
Ownership percentage	100%

Short-term Investment (Details)

Short-term Investment (Details) - USD ($)		9 Months Ended
	Feb. 14, 2022	Jul. 31, 2024
Short-term Investment [Line Items]
Investment cost	$ 501,938
Total proceeds		$ 78,500
Net realized loss		$ (7,612)
Ordinary shares [member] | Medigus Ltd [Member]
Short-term Investment [Line Items]
Number of shares issued (in Shares)	27,778

Short-term Investment (Detail_2

Short-term Investment (Details) - Schedule of Ordinary Shares of Medigus - Medigus Ltd [Member] - USD ($)	9 Months Ended
	Jul. 31, 2024	Jul. 31, 2023
Schedule of Fair Value of Common Shares [Line Items]
Beginning shares	$ 86,112	$ 193,750
Additions / Disposals	78,500
Net realized gain	(7,612)	(107,638)
Ending shares		$ 86,112

Related Party Transactions (Det

Related Party Transactions (Details)						3 Months Ended		9 Months Ended
	Jun. 13, 2024 USD ($) m²	Jun. 13, 2024 ILS (₪) m²	Mar. 31, 2024 USD ($)	Dec. 25, 2023 USD ($) m²	Dec. 25, 2023 ILS (₪) m²	Jul. 31, 2024 USD ($)	Jul. 31, 2023 USD ($)	Jul. 31, 2024 USD ($)	Jul. 31, 2023 USD ($)	Oct. 31, 2023 USD ($)
Related Party Transactions [Line Items]
Percentage of joint venture rights								50%
Research and development expenses						$ 345,883	$ 263,954	$ 896,317	$ 1,169,156
Owed to the company						108,597		$ 108,597		$ 136,002
Space for office (in Square Meters) | m²	193	193		120	120
Rent expense	$ 3,400	₪ 12,500		$ 6,500	₪ 23,300
Borrowing rate	10%	10%		10%	10%
Termination fees			$ 13,000
Fees to broker			$ 3,000
SciSparc Ltd [Member]
Related Party Transactions [Line Items]
Percentage of joint venture rights								50%
Research and development expenses						4,080	$ 126,661	$ 26,888	$ 126,661
Owed to the company						$ 108,597		$ 108,597		$ 136,002
Space for office (in Square Meters) | m²	386	386		240	240

Related Party Transactions (D_2

Related Party Transactions (Details) - Schedule of Key Management Personnel for Services - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023
Officers [Member]
Related Party Transaction [Line Items]
Consulting and Directors’ fees	$ 86,792	$ 98,167	$ 335,066	$ 318,668
Share based compensation	103,977	31,709	251,717	107,089
key management personnel compensation	190,769	129,876	586,783	425,757
Directors [Member]
Related Party Transaction [Line Items]
Consulting and Directors’ fees	58,538	41,022	184,063	121,998
Share based compensation	101,157	28,558	310,069	106,682
key management personnel compensation	$ 159,695	$ 69,580	$ 494,132	$ 228,680

Related Party Transactions (D_3

Related Party Transactions (Details) - Schedule of Balances with Related Parties - USD ($)	Jul. 31, 2024	Oct. 31, 2023
Schedule of Balances with Related Parties [Line Items]
Balances with related parties	$ 48,577	$ 42,433
Amounts Owed to Officers [Member]
Schedule of Balances with Related Parties [Line Items]
Balances with related parties	29,625	29,666
Amounts Owed to Directors [Member]
Schedule of Balances with Related Parties [Line Items]
Balances with related parties	$ 18,952	$ 12,767

Derivative Warrant Liabilitie_2

Derivative Warrant Liabilities (Details) - USD ($)							1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 28, 2024	Mar. 22, 2024	Feb. 23, 2024	Jan. 21, 2024	Jan. 16, 2024	Dec. 05, 2023	Jul. 16, 2024	Mar. 22, 2024	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023	Oct. 31, 2023	Sep. 18, 2023	Apr. 06, 2023
Derivative Warrant Liabilities [Line Items]
Number of warrants shares							138,320
Warrants exercised common share							138,320
Gain on revaluation total derivative warrants liabilities (in Dollars)									$ (643,225)	$ 482,331	$ (83,080)	$ 121,774	$ 2,189,986
April 2023 Warrants [Member]
Derivative Warrant Liabilities [Line Items]
Warrants issued															4,505,718
Warrant price per share (in Dollars per share)				$ 1.077
Convertible common shares	112,975	20,245		0.724		652,521
Number of warrants shares	156,098	27,793				2,729,394
September 2023 Warrants [Member]
Derivative Warrant Liabilities [Line Items]
Warrants issued														7,500,000
Warrant price per share (in Dollars per share)				$ 1.077
Convertible common shares	54,877			0.288
Number of warrants shares	182,144					4,602,916		281,910
Warrants exercised common share						409,667		81,469
January 2024 Warrants [Member]
Derivative Warrant Liabilities [Line Items]
Warrants issued					1,500,000
Warrant price per share (in Dollars per share)					$ 1.6
Number of warrants shares			30,200
Warrants exercised common share			30,200
Gain on revaluation total derivative warrants liabilities (in Dollars)											$ 83,080

Derivative Warrant Liabilitie_3

Derivative Warrant Liabilities (Details) - Schedule of Binomial Model was used to Measure the Derivative Warrant Liability	9 Months Ended
	Jul. 31, 2024 Duration $ / shares
Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Line Items]
Share Price (in Dollars per share)	$ 1.66
Dividend yield	0%
Bottom of Range [Member]
Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Line Items]
Exercise Price (in Dollars per share)	$ 1.077
Expected life (in Duration) | Duration	3.68
Risk-free interest rate	4%
Expected volatility	149.52%
Top of Range [Member]
Schedule of Binomial Model was Used to Measure the Derivative Warrant Liability [Line Items]
Exercise Price (in Dollars per share)	$ 1.6
Expected life (in Duration) | Duration	4.46
Risk-free interest rate	4.07%
Expected volatility	152.96%

Derivative Warrant Liabilitie_4

Derivative Warrant Liabilities (Details) - Schedule of Changes in the Warrants Liability - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Jul. 31, 2024	Jul. 31, 2023	Oct. 31, 2023
Schedule of Changes in the Warrants Liability [Line Items]
Balance at beginning			$ 4,310,379
Exercise of warrants					(574,040)
Changes in fair value of warrants	$ (643,225)	$ 482,331	(83,080)	$ 121,774	2,189,986
Balance at ending	4,314,223		4,314,223		4,310,379
April 2023 Warrants [Member]
Schedule of Changes in the Warrants Liability [Line Items]
Issuance of Warrants					1,771,208
September 2023 Warrants [Member]
Schedule of Changes in the Warrants Liability [Line Items]
Issuance of Warrants					$ 923,225
January 2024 Warrants [Member]
Schedule of Changes in the Warrants Liability [Line Items]
Issuance of Warrants			480,004
Exercise of warrants			(559,240)
Changes in fair value of warrants			83,080
Balance at ending	$ 4,314,223		$ 4,314,223

Share Capital (Details)

Share Capital (Details)																	1 Months Ended	6 Months Ended	9 Months Ended
	Jul. 04, 2024 USD ($) shares	Jun. 17, 2024 USD ($) shares	May 09, 2024 USD ($) shares	Apr. 03, 2024 USD ($) shares	Mar. 02, 2024 USD ($)	Feb. 19, 2024 USD ($) shares	Jan. 16, 2024 USD ($) $ / shares shares	Dec. 05, 2023 USD ($) shares	Nov. 06, 2023 USD ($) shares	Jun. 10, 2023 USD ($) shares	Jun. 01, 2023 USD ($) shares	May 23, 2023 USD ($) shares	Apr. 06, 2023 USD ($) $ / shares shares	Feb. 22, 2023 USD ($) shares	Jan. 16, 2023 USD ($) shares	Nov. 14, 2022 USD ($) $ / shares shares	Jul. 16, 2024 USD ($) shares	Apr. 30, 2024 USD ($) $ / shares shares	Jul. 31, 2024 USD ($) shares	Jul. 08, 2024 shares	Jun. 29, 2024 shares	Oct. 31, 2023 shares	Nov. 17, 2022 USD ($)
Share Capital [Line Items]
Common shares fair value (in Dollars) | $						$ 68			$ 117			$ 27,965
Number of warrant shares																	138,320
Gross proceeds (in Dollars) | $					$ 157,918		$ 2,400,000
Underwritten public offering							1,468,000						103,249
Warrants purchase													46,942
Purchase common shares							1,500,000
Unregistered common warrants							1,500,000
Expire term							5 years
Net proceeds from offering (in Dollars) | $							$ 1,824,773											$ 2,936,079
Exercised shares					131,914
Fair value of RSU (in Dollars) | $	$ 103,387	$ 243,003	$ 127	$ 11,935						$ 10,000	$ 48,194	1,494		$ 110,096	$ 39,975				$ 256,252
Issuance of common share																38,462
Purchase price per share (in Dollars per share) | $ / shares																		$ 195
Aggregate gross proceeds (in Dollars) | $							$ 2,400,000						$ 3,500,000			$ 7,500,000
Additional common shares																		5,769
Common shares percentage																		15%
Received underwriter warrants																		1,923
Fair value of underwriter warrants (in Dollars) | $																		$ 337,579
Public per share (in Dollars per share) | $ / shares													$ 23.4
Pre-funded warrants purchased (in Dollars per share) | $ / shares													23.37
Pre-funded warrants were exercisable (in Dollars per share) | $ / shares													0.03
Exercise price per common share (in Dollars per share) | $ / shares													$ 23.4
Fair value issued (in Dollars) | $												$ 110,000
Common Shares [Member]
Share Capital [Line Items]
Number of shares outstanding																			3,979,243			607,337
Number of shares issued	64,617		88	9,000		44			45	597	245	239		400	161				3,979,243	134,868		607,337
Purchase common shares							32,000
Purchase price per share (in Dollars per share) | $ / shares																$ 195
Net proceeds from offering post (in Dollars) | $																							$ 6,363,906
Payment per share (in Dollars per share) | $ / shares																		$ 243.75
Medigus SPA [Member]
Share Capital [Line Items]
Number of shares issued																					1,494
Warrants [Member]
Share Capital [Line Items]
Exercise price (in Dollars per share) | $ / shares							$ 1.6
Common Shares [Member]
Share Capital [Line Items]
Number of shares issued		162,970
April 2023 Warrants [Member]
Share Capital [Line Items]
Number of warrant shares								1,062,188
September 2023 Warrants [Member]
Share Capital [Line Items]
Gross proceeds (in Dollars) | $								$ 3,498,032
Pre-Funded Warrants [Member]
Share Capital [Line Items]
Warrants purchase							32,000
Exercise price (in Dollars per share) | $ / shares							$ 0.0001
April 2023 Public Offering Warrant [Member]
Share Capital [Line Items]
Number of warrant shares																	306,172
Gross proceeds (in Dollars) | $																	$ 402,206
Expire term													5 years
Warrants [Member]
Share Capital [Line Items]
Number of shares issued																					75

Share Capital (Details) - Sched

Share Capital (Details) - Schedule of the Fair Value of Underwriters Warrants - Option pricing model [member]	9 Months Ended
	Jul. 31, 2024
Schedule of the Fair Value of Underwriters Warrants [Line Items]
Risk-free interest rate	1.43%
Expected life (in years)	5
Expected volatility	150%

Warrants (Details)

Warrants (Details)	9 Months Ended
	Jul. 31, 2024 shares
April 2023 Warrants [Member]
Share Purchase Warrants [Line Items]
Warrants converted into shares	584,545
September 2023 Warrant [Member]
Share Purchase Warrants [Line Items]
Warrants converted into shares	700,880

Warrants (Details) - Schedule o

Warrants (Details) - Schedule of Warrants		9 Months Ended	12 Months Ended
		Jul. 31, 2024 $ / shares shares	Oct. 30, 2023 $ / shares shares
Schedule of Warrants [Abstract]
Number of share, Balance beginning		11,231,465	19,763
Historic weighted average price, Balance beginning (in Dollars per share) | $ / shares		$ 7.9	$ 576.66
Number of warrants, Issuance of underwriter warrants			1,923
Historic weighted average exercise price, Issuance of underwriter warrants			243.75
Number of warrants, Issuance of warrants		1,500,000	4,505,718	[1]
Historic weighted average exercise price, Issuance of warrants (in Dollars per share) | $ / shares		$ 1.6	$ 5.124	[1]
Number of warrants, Issuance of warrants	[2]		7,500,000
Historic weighted average exercise price, Issuance of warrants (in Dollars per share) | $ / shares	[2]		$ 9
Number of warrants, Issuance of XYLO warrants			75
Historic weighted average exercise price, Issuance of XYLO warrants			1,297.67
Number of warrants, Expiration of warrants		(8,333)	(11,430)
Historic weighted average exercise price, Expiration of warrants		98.43	922.98
Number of warrants, Exercise of warrants		(8,148,955)	(784,584)
Historic weighted average exercise price, Exercise of warrants (in Dollars per share) | $ / shares		$ 2.69	$ 5.124
Number of share, Balance ending		4,574,177	11,231,465
Historic weighted average price, Balance ending (in Dollars per share) | $ / shares		$ 1.56	$ 7.9
Number of warrants, Number of shares to be issued from the exercise of warrants		2,618,903
Number of warrants, Number of shares to be issued from the exercise of warrants		826,781
[1]These warrants convert into 584,545 shares.[2]These warrants convert into 700,880 shares.

Warrants (Details) - Schedule_2

Warrants (Details) - Schedule of Warrants Outstanding	12 Months Ended
	Jul. 31, 2024 $ / shares shares	Jul. 31, 2024 $ / shares shares
Schedule of Warrants Were Outstanding [Line Items]
Number of warrants outstanding	4,574,177	4,574,177
Number of shares to be issued from the exercise of warrants (warrant shares)	2,618,903	2,618,903
Expiry date November 17, 2027 [Member]
Schedule of Warrants Were Outstanding [Line Items]
Number of warrants outstanding	1,923	1,923
Number of shares to be issued from the exercise of warrants (warrant shares)	1,923	1,923
Exercise price per warrant shares (in Dollars per share and Dollars per share) | $ / shares	$ 243.75
Expiry date	Nov. 17, 2027
Expiry date November 17, 2027 [Member] | Canada, Dollars
Schedule of Warrants Were Outstanding [Line Items]
Exercise price per warrant shares (in Dollars per share and Dollars per share) | $ / shares		$ 336.59
Expiry date April 5, 2028 [Member]
Schedule of Warrants Were Outstanding [Line Items]
Number of warrants outstanding	807,669	807,669
Number of shares to be issued from the exercise of warrants (warrant shares)	584,545	584,545
Exercise price per warrant shares (in Dollars per share and Dollars per share) | $ / shares	$ 1.077
Expiry date	Apr. 05, 2028
Expiry date April 5, 2028 [Member] | Canada, Dollars
Schedule of Warrants Were Outstanding [Line Items]
Exercise price per warrant shares (in Dollars per share and Dollars per share) | $ / shares		$ 1.077
Expiry date November 23, 2024 [Member]
Schedule of Warrants Were Outstanding [Line Items]
Number of warrants outstanding	75	75
Number of shares to be issued from the exercise of warrants (warrant shares)	75	75
Exercise price per warrant shares (in Dollars per share and Dollars per share) | $ / shares	$ 1,303.49
Expiry date	Nov. 23, 2024
Expiry date November 23, 2024 [Member] | Canada, Dollars
Schedule of Warrants Were Outstanding [Line Items]
Exercise price per warrant shares (in Dollars per share and Dollars per share) | $ / shares		$ 1,800
Expiry date September 17, 2028 [Member]
Schedule of Warrants Were Outstanding [Line Items]
Number of warrants outstanding	2,433,030	2,433,030
Number of shares to be issued from the exercise of warrants (warrant shares)	700,880	700,880
Exercise price per warrant shares (in Dollars per share and Dollars per share) | $ / shares	$ 1.077
Expiry date	Sep. 17, 2028
Expiry date September 17, 2028 [Member] | Canada, Dollars
Schedule of Warrants Were Outstanding [Line Items]
Exercise price per warrant shares (in Dollars per share and Dollars per share) | $ / shares		$ 1.077
Expiry date January 15, 2029 [Member]
Schedule of Warrants Were Outstanding [Line Items]
Number of warrants outstanding	1,331,480	1,331,480
Number of shares to be issued from the exercise of warrants (warrant shares)	1,331,480	1,331,480
Exercise price per warrant shares (in Dollars per share and Dollars per share) | $ / shares	$ 1.6
Expiry date	Jan. 15, 2029
Expiry date January 15, 2029 [Member] | Canada, Dollars
Schedule of Warrants Were Outstanding [Line Items]
Exercise price per warrant shares (in Dollars per share and Dollars per share) | $ / shares		$ 1.6

Stock Options (Details)

Stock Options (Details) - USD ($)		3 Months Ended		9 Months Ended
	Nov. 14, 2023	Jul. 30, 2024	Jul. 30, 2023	Jul. 31, 2024	Jul. 31, 2023
Stock Options [Line Items]
Issued and outstanding common shares	20%			2%
Options vest expiration	10 years
Share-based compensation expense		$ 14,879	$ 59,513	$ 71,793	$ 181,448
Bottom of Range [Member]
Stock Options [Line Items]
Issued and outstanding common shares				5%
Top of range [Member]
Stock Options [Line Items]
Issued and outstanding common shares				15%

Stock Options (Details) - Sched

Stock Options (Details) - Schedule of Changes in Stock Options	9 Months Ended		12 Months Ended
	Jul. 31, 2024 $ / shares	Jul. 31, 2024 $ / shares $ / shares	Oct. 31, 2023 $ / shares	Oct. 31, 2023 $ / shares	Jul. 31, 2024 $ / shares
Schedule of Changes in Stock Options [Abstract]
Number of options Outstanding, Beginning balance	5,588	5,588	5,254	5,254
Weighted average exercise price Outstanding, Beginning balance | (per share)	$ 434.81	$ 603.12	$ 450.64	$ 613.5
Number of options, Granted			334	334
Weighted average exercise price, Granted | (per share)			$ 318.81	$ 442.22
Number of options Outstanding, Ending balance	5,521	5,521	5,588	5,588
Weighted average exercise price Outstanding, Ending balance | (per share)	$ 435.73	$ 601.7	$ 434.81	$ 603.12
Number of options Outstanding, Exercisable	5,160	5,160			5,160
Weighted average exercise price Outstanding, Exercisable | (per share)	$ 436.82	$ 436.82			$ 603.2
Number of options, Expired	(67)	(67)
Weighted average exercise price, Expired | (per share)	$ 533.14	$ 720

Stock Options (Details) - Sch_2

Stock Options (Details) - Schedule of Additional Information Regarding Stock Options Outstanding	9 Months Ended
	Jul. 31, 2024 $ / shares	Jul. 31, 2024 $ / shares
Stock Outstanding [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	5,521	5,521
Weighted average remaining contractual life (years) Outstanding	4 years 10 months 28 days
Weighted average exercise price Outstanding | (per share)	$ 435.73	$ 601.7
Stock Outstanding [Member] | 533 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	533	533
Weighted average remaining contractual life (years) Outstanding	1 year 9 months 25 days
Weighted average exercise price Outstanding | (per share)	$ 120.57	$ 166.5
Stock Outstanding [Member] | 978 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	978	978
Weighted average remaining contractual life (years) Outstanding	7 years 6 months 3 days
Weighted average exercise price Outstanding | (per share)	$ 364.98	$ 504
Stock Outstanding [Member] | 1,166 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	1,166	1,166
Weighted average remaining contractual life (years) Outstanding	1 year 9 months 25 days
Weighted average exercise price Outstanding | (per share)	$ 488.81	$ 675
Stock Outstanding [Member] | 200 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	200	200
Weighted average remaining contractual life (years) Outstanding	4 years 9 months
Weighted average exercise price Outstanding | (per share)	$ 508.36	$ 702
Stock Outstanding [Member] | 133 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	133	133
Weighted average remaining contractual life (years) Outstanding	2 years 1 month 20 days
Weighted average exercise price Outstanding | (per share)	$ 540.95	$ 747
Stock Outstanding [Member] | 422 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	422	422
Weighted average remaining contractual life (years) Outstanding	7 years 4 months 9 days
Weighted average exercise price Outstanding | (per share)	$ 443.19	$ 612
Stock Outstanding [Member] | 1,044 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	1,044	1,044
Weighted average remaining contractual life (years) Outstanding	7 years 6 months 3 days
Weighted average exercise price Outstanding | (per share)	$ 521.4	$ 720
Stock Outstanding [Member] | 667 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	667	667
Weighted average remaining contractual life (years) Outstanding	1 year 11 months 1 day
Weighted average exercise price Outstanding | (per share)	$ 547.47	$ 756
Stock Outstanding [Member] | 111 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	111	111
Weighted average remaining contractual life (years) Outstanding	7 years 4 months 9 days
Weighted average exercise price Outstanding | (per share)	$ 651.75	$ 900
Stock Outstanding [Member] | 61 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	61	61
Weighted average remaining contractual life (years) Outstanding	8 years 9 months 25 days
Weighted average exercise price Outstanding | (per share)	$ 228.11	$ 315
Stock Outstanding [Member] | 156 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	156	156
Weighted average remaining contractual life (years) Outstanding	8 years 10 months 28 days
Weighted average exercise price Outstanding | (per share)	$ 364.98	$ 504
Stock Outstanding [Member] | 50 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Outstanding	50	50
Weighted average remaining contractual life (years) Outstanding	8 years 11 months 8 days
Weighted average exercise price Outstanding | (per share)	$ 23.4	$ 32.31
Stock Exercisable [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	5,160	5,160
Weighted average exercise price, Exercisable | (per share)	$ 436.82	$ 603.2
Stock Exercisable [Member] | 533 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	533	533
Weighted average exercise price, Exercisable | (per share)	$ 120.57	$ 166.5
Stock Exercisable [Member] | 978 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	858	858
Weighted average exercise price, Exercisable | (per share)	$ 364.98	$ 504
Stock Exercisable [Member] | 1,166 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	1,166	1,166
Weighted average exercise price, Exercisable | (per share)	$ 488.81	$ 675
Stock Exercisable [Member] | 200 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	192	192
Weighted average exercise price, Exercisable | (per share)	$ 508.36	$ 702
Stock Exercisable [Member] | 133 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	133	133
Weighted average exercise price, Exercisable | (per share)	$ 540.95	$ 747
Stock Exercisable [Member] | 422 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	422	422
Weighted average exercise price, Exercisable | (per share)	$ 443.19	$ 612
Stock Exercisable [Member] | 1,044 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	870	870
Weighted average exercise price, Exercisable | (per share)	$ 521.4	$ 720
Stock Exercisable [Member] | 667 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	667	667
Weighted average exercise price, Exercisable | (per share)	$ 547.47	$ 756
Stock Exercisable [Member] | 111 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	102	102
Weighted average exercise price, Exercisable | (per share)	$ 651.75	$ 900
Stock Exercisable [Member] | 61 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	53	53
Weighted average exercise price, Exercisable | (per share)	$ 228.11	$ 315
Stock Exercisable [Member] | 156 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	143	143
Weighted average exercise price, Exercisable | (per share)	$ 364.98	$ 504
Stock Exercisable [Member] | 50 [Member]
Schedule of Additional Information Regarding Stock Options Outstanding [Line Items]
Number of stock options, Exercisable	21	21
Weighted average exercise price, Exercisable | (per share)	$ 23.4	$ 32.31

Stock Options (Details) - Sch_3

Stock Options (Details) - Schedule of Fair Value of Stock Options - Black-Schole option pricing model [Member]	9 Months Ended
	Jul. 31, 2024	Jul. 31, 2023
Schedule of Fair Value of Stock Options [Line Items]
Risk-free interest rate	4.05%	3.83%
Expected life (in years)	4.86	5.86
Bottom of Range [Member]
Schedule of Fair Value of Stock Options [Line Items]
Expected volatility	121.10%	111%
Top of Range [Member]
Schedule of Fair Value of Stock Options [Line Items]
Expected volatility	133.14%	116%

Restricted Share Units (Details

Restricted Share Units (Details) - USD ($)	9 Months Ended
	Jul. 31, 2024	Jul. 31, 2023
Restricted Share Units [Line Items]
Fair value	$ 629,720	$ 90,598
RSU's [Member]
Restricted Share Units [Line Items]
Restricted shares units, issued	457,981
Consultants, Directors and Officers [Member] | RSU's [Member]
Restricted Share Units [Line Items]
Restricted shares units, issued	476,189

Restricted Share Units (Detai_2

Restricted Share Units (Details) - Schedule of Continuity of RSUs - Restricted Stock Units [Member]	9 Months Ended				12 Months Ended
	Jul. 31, 2024 $ / shares		Jul. 31, 2024 $ / shares $ / shares		Oct. 31, 2023 $ / shares	Oct. 31, 2023 $ / shares $ / shares	Jul. 31, 2024 $ / shares	Oct. 31, 2023 $ / shares
Schedule of Continuity of RSUs [Line Items]
Number of share, Balance beginning
Weighted average price, Balance beginning | (per share)	$ 1.1		$ 1.1				$ 1.52
Number of RSUs, Granted	476,189	[1]	476,189	[1]	2,200	2,200
Weighted average issue price, Granted | (per share)	$ 1.34	[1]	$ 1.85	[1]	$ 41.46	$ 55.97
Number of RSUs, Vested	(457,981)		(457,981)		(2,200)	(2,200)
Weighted average issue price, Vested | (per share)	$ 1.37		$ 1.86		$ 41.46	$ 55.97
Number of share, Balance ending	18,208		18,208
Weighted average price, Balance ending | (per share)	$ 1.1		$ 1.1				$ 1.52
[1]During the nine months ended July 31, 2024, the Company issued 476,189 RSU’s to consultants, directors and officers. 457,981 RSU’s vested with a fair value of $629,720 (2023-$90,598).

Financial Instruments and Ris_3

Financial Instruments and Risk Management (Details)	9 Months Ended
	Jul. 31, 2024
Financial Instruments and Risk Management [Line Items]
Foreign currency, percentage	10%
Foreign Exchange Rate Risk [Member]
Financial Instruments and Risk Management [Line Items]
Foreign currency, percentage	10%

Financial Instruments and Ris_4

Financial Instruments and Risk Management (Details) - Schedule of Assets and Liabilities Measured at Fair Value - USD ($)	Jul. 31, 2024	Oct. 31, 2023
Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Derivative warrants liability	$ 4,314,223	$ 4,310,379
Short-term investment		86,112
Quoted prices in active markets for identical instruments (Level 1) [Member]
Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Derivative warrants liability
Short-term investment		86,112
Significant other observable inputs (Level 2) [Member]
Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Derivative warrants liability
Short-term investment
Significant unobservable inputs (Level 3) [Member]
Schedule of Assets and Liabilities Measured at Fair Value [Line Items]
Derivative warrants liability	$ 4,314,223	4,310,379
Short-term investment

Financial Instruments and Ris_5

Financial Instruments and Risk Management (Details) - Schedule of Foreign Currency Exchange Risk on Net Working Capital - Foreign Exchange Rate Risk [Member]	9 Months Ended
	Jul. 31, 2024 USD ($)
Financial Instruments And Risk Management [Line Items]
Cash and cash equivalents	$ 75,440
Other receivables	62,380
Accounts payable and accrued liabilities	(105,839)
Due to related parties	(38,577)
Total foreign currency financial assets and liabilities	(6,596)
Impact of a 10% strengthening or weakening of foreign exchange rate	$ (660)

Financial Instruments and Ris_6

Financial Instruments and Risk Management (Details) - Schedule of Foreign Currency Exchange Risk on Net Working Capital (Parentheticals)	9 Months Ended
	Jul. 31, 2024
Foreign Exchange Rate Risk [Member]
Financial Instruments And Risk Management [Line Items]
Impact of a strengthening or weakening of foreign exchange rate	10%

Financial Instruments and Ris_7

Financial Instruments and Risk Management (Details) - Schedule of Contractual Maturities of Financial Liabilities - USD ($)	Jul. 31, 2024	Oct. 31, 2023
Financial Instruments and Risk Management [Line Items]
Accounts payable and accrued liabilities	$ 276,744	$ 617,004
Due to related parties	48,577	42,433
Lease liability	60,898
Total	386,219	659,437
Within 1 year [Member]
Financial Instruments and Risk Management [Line Items]
Accounts payable and accrued liabilities	276,744	617,004
Due to related parties	48,577	42,433
Lease liability	35,320
Total	360,641	659,437
Within 2-5 years [Member]
Financial Instruments and Risk Management [Line Items]
Accounts payable and accrued liabilities
Due to related parties
Lease liability	25,578
Total	$ 25,578

Commitments (Details)

Commitments (Details) - USD ($)	Mar. 30, 2024	Mar. 19, 2024	Jan. 15, 2024
Commitments [Line Items]
Percentage of royalties	3%	3%	2.50%
Annual license fee	$ 25,000	$ 25,000
Payment from company	600,000	600,000
Bottom of range [Member]
Commitments [Line Items]
Annual license fee	35,000	35,000
Top of range [Member]
Commitments [Line Items]
Annual license fee	50,000	50,000
Yissum Research Development Company [Member]
Commitments [Line Items]
Payment from company	$ 400,000	$ 400,000

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Events [Member]	Aug. 12, 2024 USD ($)
Subsequent Events [Line Items]
Gross proceeds	$ 74,999
April 2023 Warrants [Member]
Subsequent Events [Line Items]
Warrants exercised	69,592